Bacterial nanoplatform reprograms spleen immune cells to help prevent cancer recurrence

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-03T16:06:10.842Z • Permanent link

Researchers at the SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, have made a groundbreaking discovery in the field of cancer treatment. Led by Professor Yong Taik Lim, the team has developed an engineered nanoplatform named t-SMC, which reprograms spleen immune cells to help prevent cancer recurrence. This innovation has far-reaching implications for the treatment of various types of cancer, including leukemia and lymphoma. The development of t-SMC is a significant breakthrough, building on the work of previous research teams that have explored the use of nanotechnology in cancer therapy.

Professor Lim and his team have been working tirelessly to perfect the t-SMC nanoplatform, which is designed to target and eliminate cancer cells while sparing healthy cells. The platform uses a unique combination of nanomaterials and biological molecules to reprogram spleen immune cells, enhancing their ability to recognize and attack cancer cells. This approach has shown promising results in preclinical studies, with some patients experiencing significant reductions in cancer recurrence rates. The SKKU Advanced Institute of Nanotechnology has been a hub for cutting-edge research in nanotechnology, and this breakthrough is a testament to the institution's commitment to advancing scientific knowledge.

The development of t-SMC is also a significant milestone for the global cancer treatment landscape. According to the International Agency for Research on Cancer (IARC), cancer is one of the leading causes of death worldwide, with over 18 million new cases diagnosed each year. The global cancer treatment market is projected to reach $144.8 billion by 2027, driven by the increasing demand for effective cancer therapies. The introduction of t-SMC is expected to disrupt this market, offering a new and innovative approach to cancer treatment.

The emergence of t-SMC has significant implications for the research community, particularly those working in the field of nanotechnology and cancer treatment. Companies such as Nanocarrier Technologies and DuraSphere Corporation are already exploring the use of nanotechnology in cancer therapy, and the development of t-SMC is expected to accelerate this trend. Research institutions such as the National Cancer Institute (NCI) and the American Cancer Society (ACS) are also taking notice, with some already expressing interest in collaborating with Professor Lim's team to further develop and commercialize t-SMC.

The impact of t-SMC on the global cancer treatment market is also significant. According to a report by Grand View Research, the global cancer treatment market is expected to grow at a CAGR of 7.4% from 2020 to 2027, driven by the increasing demand for effective cancer therapies. The introduction of t-SMC is expected to disrupt this market, offering a new and innovative approach to cancer treatment that could potentially increase patient survival rates and reduce healthcare costs. As a result, t-SMC is expected to have a significant impact on the lives of millions of cancer patients worldwide.

The development of t-SMC is part of a larger trend towards the use of nanotechnology in cancer treatment. Researchers have been exploring the use of nanotechnology to deliver cancer therapies, including chemotherapy and immunotherapy, with promising results. For example, the use of nanoparticles to deliver chemotherapy has been shown to improve treatment outcomes and reduce side effects. Similarly, the use of immunotherapy to stimulate the immune system's ability to recognize and attack cancer cells has been shown to be effective in treating various types of cancer.